Pediatric Infectious Disease

Register      Login

VOLUME 3 , ISSUE 2 ( April-June, 2021 ) > List of Articles

REVIEW ARTICLE

Current Evidence on Coronavirus Disease-2019: A Comprehensive Review

Mangla Sood, Seema Sharma

Keywords : COVID-19, Pandemic, Severe acute respiratory syndrome-associated coronavirus-2

Citation Information : Sood M, Sharma S. Current Evidence on Coronavirus Disease-2019: A Comprehensive Review. Pediatr Inf Dis 2021; 3 (2):65-73.

DOI: 10.5005/jp-journals-10081-1286

License: CC BY-NC 4.0

Published Online: 14-07-2021

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Coronavirus disease-2019 (COVID-19) pandemic has become an unprecedented public health challenge for clinicians and policymakers across the globe. COVID-19, the infectious disease caused by the novel coronavirus severe acute respiratory syndrome-associated coronavirus-2 (SARS-CoV-2), has been shown to affect all ages, particularly, the aged and elderly, and has reached massive proportions globally. We aim to review the current clinical epidemiology, pathophysiology, clinical presentations, and treatment for this rapidly growing novel disease globally, and discuss infection prevention, control, and management strategies put forth by World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), the Ministry of Health and Family Welfare (MoHFW) to the Govt of India, and Indian Council of Medical Research (ICMR) for this huge public health concern. Reviewing the current evidence for COVID-19 is imperative to help understand effective preventive and treatment measures for this novel threat to humanity.


PDF Share
  1. WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard. Accessed November 26, 2020. https://covid19.who.int/.
  2. Cascella M, Rajnik M, Cuomo A, et al. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls Publishing; 2020. Accessed October 30, 2020 http://www.ncbi.nlm.nih.gov/pubmed/32150360.
  3. Lam TT-Y, Jia N, Zhang Y-W, et al. Identifying SARS-CoV-2-related coronaviruses in Malayan Pangolins. Nature 2020;583(7815):282–285. DOI: 10.1038/s41586-020-2169-0.
  4. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8(4):420–422. DOI: 10.1016/S2213-2600(20)30076-X.
  5. Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 2020;395(10235):1517–1520. DOI: 10.1016/S0140-6736(20)30920-X.
  6. Wei WE, Li Z, Chiew CJ, et al. Presymptomatic transmission of SARS-CoV-2—Singapore, January 23–March 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69(14):411–415. DOI: 10.15585/mmwr.mm6914e1.
  7. Chin AWH, Chu JTS, Perera MRA, et al. Stability of SARS-CoV-2 in different environmental conditions. Lancet Microbe 2020;1(1):e10. DOI: 10.1016/S2666-5247(20)30003-3.
  8. Chawla D, Chirla D, Dalwai S, et al. Perinatal-neonatal management of COVID-19 infection - guidelines of the Federation of Obstetric and Gynaecological Societies of India (FOGSI), National Neonatology Forum of India (NNF), and Indian Academy of Pediatrics (IAP). Indian Pediatr 2020;57(6):536–548. DOI: 10.1007/s13312-020-1852-4. http://www.ncbi.nlm.nih.gov/pubmed/32238615.
  9. Sun J, Xiao J, Sun R, et al. Prolonged persistence of SARS-CoV-2 RNA in body fluids. Emerg Infect Dis 2020;26(8):1834–1838. DOI: 10.3201/eid2608.201097.
  10. Laboratory testing strategy recommendations for COVID-19: interim guidance. Accessed October 30, 2020. https://www.who.int/publications/i/item/laboratory-testing-strategy-recommendations-for-covid-19-interim-guidance.
  11. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020;323(18):1843–1844. DOI: 10.1001/jama.2020.3786.
  12. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis 2020;71(16):2027–2034. DOI: 10.1093/cid/ciaa344.
  13. Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Rep 2020;69(15):458–464. DOI: 10.15585/mmwr.mm6915e3.
  14. Zarifian A, Zamiri Bidary M, Arekhi S, et al. Gastrointestinal and hepatic abnormalities in patients with confirmed COVID-19: a systematic review and meta-analysis. J Med Virol 2020(1):jmv.26314. DOI: 10.1002/jmv.26314.
  15. Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 2020;382(23):2268–2270. DOI: 10.1056/NEJMc2008597.
  16. Marraha F, Al Faker I, Gallouj S. A review of the dermatological manifestations of coronavirus disease 2019 (COVID-19). Dermatol Res Pract 2020;2020:1–9. DOI: 10.1155/2020/9360476.
  17. Spinato G, Fabbris C, Polesel J, et al. Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection. JAMA 2020;323(20):2089. DOI: 10.1001/jama.2020.6771.
  18. Dhochak N, Singhal T, Kabra SK, et al. Pathophysiology of COVID-19: Why children fare better than adults? Indian J Pediatr 2020;87(7):537–546. DOI: 10.1007/s12098-020-03322-y.
  19. Coronavirus Disease 2019 (COVID-19) | CDC. Accessed October 30, 2020. https://www.cdc.gov/coronavirus/2019-ncov/index.html.
  20. World Health Organization. Multisystem Inflammatory Syndrome in Children and Adolescents Temporally Related to COVID-19.; 2020. Accessed November 9, 2020. https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19.
  21. Kaushik A, Gupta S, Sood M, et al. A systematic review of multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection. Pediatr Infect Dis J 2020;39(11):e340–e346. DOI: 10.1097/INF.0000000000002888.
  22. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708–1720. DOI: 10.1056/NEJMoa2002032.
  23. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ 2020;369:m1985. DOI: 10.1136/bmj.m1985.
  24. Home-Johns Hopkins Coronavirus Resource Center. Accessed October 30, 2020. https://coronavirus.jhu.edu/.
  25. Xu L, Mao Y, Chen G. Risk factors for 2019 novel coronavirus disease (COVID-19) patients progressing to critical illness: a systematic review and meta-analysis. Aging 2020;12(12):12410–12421. DOI: 10.18632/aging.103383.
  26. Government of India. MoHFW_Home. Minist Heal Fam Welfare, Govt India. Published online 2020. Accessed October 30, 2020 https://www.mohfw.gov.in/.
  27. Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med 2020;48(6):e440–e469. DOI: 10.1097/CCM.0000000000004363.
  28. Beigel JH, Tomashek KM, Dodd LE, et al. For the treatment of Covid-19—final report. N Engl J Med 2020(19):NEJMoa2007764. DOI: 10.1056/NEJMoa2007764.
  29. Covid patients given favipiravir showed “40% faster” recovery, Glenmark trial results claim. Accessed October 30, 2020. https://theprint.in/health/covid-patients-given-favipiravir-showed-40-faster-recovery-glenmark-trial-results-claim/466327/.
  30. Chen L, Xiong J, Bao L, et al. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020;20(4):398–400. DOI: 10.1016/S1473-3099(20)30141-9.
  31. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med 2020. NEJMoa2021436. DOI: 10.1056/NEJMoa2021436.
  32. Patel K, Gooley TA, Bailey N, et al. Use of the IL-6R antagonist tocilizumab in hospitalized COVID-19 patients. J Intern Med 2020. joim.13163. DOI: 10.1111/joim.13163.
  33. Monteagudo LA, Boothby A, Gertner E. Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatol 2020;2(5):276–282. DOI: 10.1002/acr2.11135.
  34. “Solidarity” clinical trial for COVID-19 treatments. Accessed Ocyober 31, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments.
  35. Brouwer PJM, Caniels TG, van der Straten K, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 2020;369(6504):643–650. DOI: 10.1126/science.abc5902.
  36. Potere N, Valeriani E, Candeloro M, et al. Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Crit Care 2020;24(1):389. DOI: 10.1186/s13054-020-03022-1.
  37. Prescott HC, Angus DC. Enhancing recovery from sepsis. JAMA 2018;319(1):62. DOI: 10.1001/jama.2017.17687.
  38. Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network—United states, March–June 2020. MMWR Morb Mortal Wkly Rep 2020;69(30):993–998. DOI: 10.15585/mmwr.mm6930e1.
  39. Rokadiya S, Gil E, Stubbs C, et al. COVID-19: outcomes of patients with confirmed COVID-19 re-admitted to hospital. J Infect 2020;81(3):e18–e19. DOI: 10.1016/j.jinf.2020.07.007.
  40. Phelan AL. COVID-19 immunity passports and vaccination certificates: scientific, equitable, and legal challenges. Lancet 2020;395(10237):1595–1598. DOI: 10.1016/S0140-6736(20) 31034-5.
  41. Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med 2020;383(6):517–525. DOI: 10.1056/NEJMoa2016638.
  42. World Health Organization. Draft landscape of COVID-19 candidate vaccines - 15 May 2020. Who. 2020; (March):3. Accessed August 27, 2020. https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.